A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Name: A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
License: Public Domain

Mural Oncology, Inc

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

advanced solid tumors

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 426762
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.